Who are Optimised dose rifampicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rifampicin (R), Rifamycin-containing regimen, Rifampin/isoniazid FDC, HR, amoxicillin rifabutin, Rifampin (RIF).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/optimised-dose-rifampicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Optimised dose rifampicin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimised dose rifampicin (Optimised dose rifampicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic (rifamycin). Area: Infectious Disease.

phase 3 Antibiotic (rifamycin) Bacterial RNA polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Optimised dose rifampicin (Optimised dose rifampicin) — Radboud University Medical Center. Optimised dose rifampicin inhibits bacterial RNA polymerase to suppress mycobacterial protein synthesis and growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Optimised dose rifampicin TARGET	Optimised dose rifampicin	Radboud University Medical Center	phase 3	Antibiotic (rifamycin)	Bacterial RNA polymerase
Rifampicin (R)	Rifampicin (R)	University College, London	marketed	Rifamycin antibiotic	Bacterial RNA polymerase β-subunit
Rifamycin-containing regimen	Rifamycin-containing regimen	National Taiwan University Hospital	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Rifampin/isoniazid FDC	Rifampin/isoniazid FDC	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antituberculous agent (fixed-dose combination)	Bacterial RNA polymerase (rifampin); mycolic acid biosynthesis (isoniazid)
HR	HR	Global Alliance for TB Drug Development	marketed	Anti-tuberculosis agent (fixed-dose combination)	Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin)
amoxicillin rifabutin	amoxicillin rifabutin	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic (beta-lactam + rifamycin)	Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin)
Rifampin (RIF)	Rifampin (RIF)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Rifamycin antibiotic	Bacterial RNA polymerase (RNAP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic (rifamycin) class)

Radboud University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Optimised dose rifampicin — Competitive Intelligence Brief. https://druglandscape.com/ci/optimised-dose-rifampicin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing